Kidney and Survival Outcomes with Semaglutide by CKD Severity in the FLOW Trial

Clinical Journal of the American Society of Nephrology 2026 Open access

Read full text
Authors: Katherine R. Tuttle, Johannes F. E. Mann, Manuel Mayrdorfer, Brian Rayner, Giuseppe Pugliese, Richard E. Pratley, Vlado Perkovic, KW Mahaffey, Naoki Kashihara, Ole Kleist Jeppesen, Janusz Gumprecht, Ricardo Correa-Rotter
+5 more David Z.I. Cherney, Heidrun Bosch-Traberg, Mustafa Arici, Peter Rossing, on behalf of the DAHLIAS study investigators
DOI: 10.2215/cjn.0000000974
Cited by: 5
References: 33

Abstract

KEY POINTS: Semaglutide reduced kidney outcome risk across broad CKD severity strata (eGFR; albuminuria). Reduced risk for all-cause death also carried through strata of CKD severity. In a population with type 2 diabetes, semaglutide improved kidney and survival outcomes irrespective of CKD severity, including advanced CKD. BACKGROUND: Semaglutide improved kidney and overall survival in participants with type 2 diabetes (T2D) and CKD in the Evaluate Renal Function with Semaglutide Once Weekly (FLOW) trial. The aim of the present analyses was to quantify these benefits across broad strata of CKD severity. METHODS: FLOW was a double-blind, randomized, placebo-controlled trial (median follow-up 3.4 [interquartile range, 2.9-4.0] years). Participants with T2D and eGFR 50-75 ml/min per 1.73 m 2 and urine albumin-to-creatinine ratio (UACR) >300 to

Fields of Study & Subjects

Diabetes Treatment and Management Chronic Kidney Disease and Diabetes Diabetes Management and Research

Publication details

Journal / source
Clinical Journal of the American Society of Nephrology
Publisher
Ovid Technologies (Wolters Kluwer Health)
Volume
21
Issue
5
Pages
841–851
Publication date
18 February 2026
Language
EN